Nanobac Pharmaceuticals, Incorporated
NNBP · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.17 | 0.03 | 0.47 |
| FCF Yield | 0.00% | -10.85% | -34.43% | -15.48% |
| EV / EBITDA | -0.69 | -6.91 | -3.31 | -3.26 |
| Quality | ||||
| ROIC | 133.94% | 72.09% | 44.84% | 91.10% |
| Gross Margin | 17.60% | 64.54% | 65.07% | 71.96% |
| Cash Conversion Ratio | 0.14 | 0.52 | 0.64 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.06% | -14.36% | 10.80% | 214.18% |
| Free Cash Flow Growth | 64.88% | -7.97% | 29.91% | -57.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.69 | -1.26 | -0.87 | -0.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.41 | 1.20 | 1.96 | 1.42 |
| Cash Conversion Cycle | -26,811.90 | -1,564.47 | -311.01 | -2,085.18 |